HomeEndocrinologyWegovy pill sheds 6% of weight in three months – real world...

Wegovy pill sheds 6% of weight in three months – real world data

Patients who stayed on Novo’s Wegovy pill lost an average of 6.2% of their body weight over three months, according to real-world data presented at the ObesityWeek conference in Washington this week, reports Reuters.

The pill, launched in January, has helped Novo regain some ground lost to Eli Lilly, and the Danish drugmaker is trying to stay ahead of its US rival in the race for oral obesity treatments.

Novo’s chief scientific officer Martin Holst Lange said that the real-world data, presented to 4 300 participants from more than 60 countries, were ⁠encouraging, and broadly replicated the findings of 5.5% weight loss at 12 weeks seen in Novo’s late-stage trial for the pill.

Study participants, who started taking the pill between 5 January and 7 February this year, lost an average of 6.3 kg from a baseline weight of 103.0 kg, Novo said. About three-fifths lost at least 5% of their weight, and roughly one in six lost at least ​10%.

The analysis covered 5 872 adults on the Ro telehealth platform who had never taken a weight-loss drug ⁠and who stayed on the pill for the full three months.

Novo’s fortunes have declined significantly since it became Europe’s most valuable listed company after the 2021 launch of its injectable weight-loss drug Wegovy. Its stock has plummeted more than 70% from its peak as Lilly surpassed ⁠it to take the lead in the obesity-drug market.

According to company presentations earlier this month, however, oral treatments now represent roughly a third of US obesity prescriptions, with Novo securing more than 80% of ⁠new oral prescriptions.

Novo said high manufacturing output and faster approvals ​from health authorities had allowed it to speed up the rollout of the Wegovy pill. It now plans to launch it in more than 20 countries by mid-2027, compared ​with the end-2027 target given at its capital markets day in September.

CEO Mike Doustdar said in an interview that Novo had held its ground since Eli Lilly ⁠launched a rival pill.

In September, the company said separate real-world data showed patients who switched from weight-loss injections to Novo’s pill continued to lose weight.

Oral Wegovy (⁠semaglutide) led to about a 14% reduction in body weight over 64 weeks, while Eli Lilly’s obesity pill Foundayo led to about an 11% reduction over 72 weeks, separate studies have shown.

 

Reuters article – Novo’s Wegovy pill helps patients lose about 6% of weight in three months, real-world data show (Open access)

 

See more from MedicalBrief archives:

 

FDA green-lights Wegovy weight-loss pill

 

Weight loss pills a win for obesity in poor countries – experts

 

Wegovy may have highest risk of blinding condition – Canadian study

 

Higher Wegovy dose sheds more kilos – Novo tria

MedicalBrief — our free weekly e-newsletter

We'd appreciate as much information as possible, however only an email address is required.